Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 20/20 | 0.92 |
| ▸ | BCL2L1 | Q07817 | 3/20 | 0.88 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.88 |
| ▸ | BCL2L2 | Q92843 | 2/20 | 0.88 |
| ▸ | NSD2 | O96028 | 1/20 | 0.88 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.88 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.88 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.88 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.88 |
| ▸ | BID | P55957 | 1/20 | 0.88 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.88 |
| ▸ | ASPH | Q12797 | 1/20 | 0.88 |
| ▸ | BAD | Q92934 | 1/20 | 0.88 |
| ▸ | NSD1 | Q96L73 | 1/20 | 0.88 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.88 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19424451 | 0.96 | BCL2 (0.84) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| SCHEMBL1701640 | 0.96 | BCL2 (1.00) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| SCHEMBL30313999 | 0.96 | BCL2 (1.00) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| SCHEMBL19424332 | 0.95 | BCL2 (0.83) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| SCHEMBL19424540 | 0.95 | BCL2 (0.83) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| SCHEMBL19424445 | 0.95 | BCL2 (0.82) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| SCHEMBL17071344 | 0.95 | BCL2 (0.91) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| SCHEMBL22105258 | 0.95 | BCL2 (0.91) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| SCHEMBL19424518 | 0.95 | BCL2 (0.87) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| SCHEMBL19424520 | 0.95 | BCL2 (0.87) | BCL2BCL2L1MCL1BCL2L2NSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834450-B2 | Compounds having ((3-nitrophenyl)sulfonyl)acetamide as BCL-2 inhibitors | Eil Therapeutics, Inc. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11654143-B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor | ACERTA PHARMA B.V. (NL) | 2023-05-23 | — | — | US | disclosed |
| US-11166951-B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor | ACERTA PHARMA B.V. (NL) | 2021-11-09 | — | — | US | disclosed |
| US-20210169865-A1 | COMBINATION OF BCL-2 INHIBITOR AND MEK INHIBITOR FOR THE TREATMENT OF CANCER | GENENTECH INC (US) | 2021-06-10 | — | — | US | disclosed |
| US-20210113615-A1 | HETERODIMERIC INACTIVATABLE CHIMERIC ANTIGEN RECEPTORS | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD. (CH) | 2021-04-22 | — | — | US | disclosed |
| US-20180021259-A1 | DYE-STABILIZED NANOPARTICLES AND METHODS OF THEIR MANUFACTURE AND THERAPEUTIC USE | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2018-01-25 | — | — | US | disclosed |
| US-20170231986-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 Inhibitor | ACERTA PHARMA B.V. (NL) | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170231986-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 Inhibitor | BTK, JAK2, BCL9 | BCL2 7/4885BCL2L1 26/4885MCL1 30/4885 |
| US-11834450-B2 | Compounds having ((3-nitrophenyl)sulfonyl)acetamide as BCL-2 inhibitors | BCL2, BCL2A1, BCL2L1 | BCL2 1/4885BCL2L1 3/4885MCL1 18/4885 |
| US-20210169865-A1 | COMBINATION OF BCL-2 INHIBITOR AND MEK INHIBITOR FOR THE TREATMENT OF CANCER | MCL1, BCL2, BAK1 | BCL2 2/4885BCL2L1 4/4885MCL1 1/4885 |
| US-20210113615-A1 | HETERODIMERIC INACTIVATABLE CHIMERIC ANTIGEN RECEPTORS | IL2RA, PAICS, FCGR2A | BCL2 922/4885BCL2L1 2016/4885MCL1 169/4885 |
| US-11166951-B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor | BTK, JAK2, BCL9 | BCL2 7/4885BCL2L1 26/4885MCL1 30/4885 |
| US-20180021259-A1 | DYE-STABILIZED NANOPARTICLES AND METHODS OF THEIR MANUFACTURE AND THERAPEUTIC USE | TP53, HCCS, SCNN1B | BCL2 630/4885BCL2L1 405/4885MCL1 62/4885 |
| US-11654143-B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor | BTK, JAK2, BCL9 | BCL2 7/4885BCL2L1 26/4885MCL1 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.